Comparison of pulmonary metastasectomy and stereotactic body radiation therapy for the treatment of lung metastases

Petrella, Francesco; Spaggiari, Lorenzo

doi:10.21037/jtd.2019.01.72

Cited by 4 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This difference in outcome seems to especially hold for lesions larger than 2 cm (72). In retrospective studies, surgery tends to either have similar or better outcomes than radiotherapy (62,66,73). Yet, when comparing different treatment modalities using retrospective data, the results are inherently biased.…”

Section: Outcome Per Location: An Intricate Interplay Of Dose Volume and Primary Tumormentioning

confidence: 99%

Radiotherapy for oligometastatic non-small cell lung cancer: a narrative review

Sundahl

Lievens

2021

Transl Lung Cancer Res

View full text Add to dashboard Cite

Preclinical and early clinical evidence suggest that radical radiotherapy of oligometastatic disease in non-small cell lung cancer (NSCLC) patients can impact outcomes with relatively limited toxicity. Whilst data from phase 2 randomized trials suggesting an improved overall survival (OS) with this treatment is promising, it has also illustrated the heterogeneity in this patient population and treatment.Oligometastatic disease in itself comprises a broad spectrum of patients, in terms of tumor load and location, stage of the disease and treatment history. This real-life variety in patient characteristics is often reflected in studies to a certain extent, hinting to the fact that all might benefit from radical radiotherapy to limited metastatic disease, yet leaving the question unanswered as to whom the ideal candidate is. Furthermore, differences between and within studies with regards to treatment modality, timing, radiation technique, and radiation dose are substantial. Also, preclinical and early clinical trials suggest that radiotherapy can work synergistically with checkpoint inhibitors by acting as an in situ cancer vaccine, therefore the combination of these two treatments in oligometastatic patients might entail the largest benefit. Ongoing randomized controlled phase 3 trials and prospective registry trials will further elucidate the true extent of benefit of this local treatment strategy and aid in identifying the ideal patient population and therapy. The current narrative review summarizes the clinical evidence on radiotherapy for oligometastatic NSCLC and highlights the remaining unknowns.

show abstract

Section: Outcome Per Location: An Intricate Interplay Of Dose Volume and Primary Tumormentioning

confidence: 99%

Radiotherapy for oligometastatic non-small cell lung cancer: a narrative review

Sundahl

Lievens

2021

Transl Lung Cancer Res

View full text Add to dashboard Cite

show abstract

Percutaneous thermal ablation of primary and secondary lung tumors: Comparison between microwave and radiofrequency ablation

Aufranc¹,

Farouil²,

Abdel‐Rehim³

et al. 2019

Diagnostic and Interventional Imaging

View full text Add to dashboard Cite

Recent developments and advances in secondary prevention of lung cancer

Rizzo

Grande

Wannesson

et al. 2020

European Journal of Cancer Prevention

View full text Add to dashboard Cite

Lung cancer prevention may include primary prevention strategies, such as corrections of working conditions and life style – primarily smoking cessation – as well as secondary prevention strategies, aiming at early detection that allows better survival rates and limited resections. This review summarizes recent developments and advances in secondary prevention, focusing on recent technological tools for an effective early diagnosis.

show abstract

Comparison of pulmonary metastasectomy and stereotactic body radiation therapy for the treatment of lung metastases

Cited by 4 publications

References 26 publications

Radiotherapy for oligometastatic non-small cell lung cancer: a narrative review

Radiotherapy for oligometastatic non-small cell lung cancer: a narrative review

Percutaneous thermal ablation of primary and secondary lung tumors: Comparison between microwave and radiofrequency ablation

Recent developments and advances in secondary prevention of lung cancer

Contact Info

Product

Resources

About